Document is current
Any future updates will be listed below
-
Authors
Kim, Sonia B.
Shaia, Jacqueline K. https://orcid.org/0000-0001-7873-669X
Kaelber, David C.
Singh, Rishi P.
Talcott, Katherine E. https://orcid.org/0000-0003-0458-4181
-
Funding
Funding for this research was provided by:
U.S. Department of Health & Human Services | NIH | National Center for Advancing Translational Sciences (UL1TR002548)
Research to Prevent Blindness (P30EY025585(BA-A))
- License Information
-
More Information
Article History
Received: 6 November 2024
Revised: 24 March 2025
Accepted: 27 March 2025
First Online: 10 April 2025
Competing interests
: DK reports personal fees from Dynavax Technologies Corporation. RS reports personal fees from Apellis, Iveric Bio, Eyepoint, Regenxbio, Genentech, Bausch and Lomb, Zeiss, Alcon, and Regeneron, and research grants from Janssen. KT reports personal fees from Alimera, Abbvie, Apellis, Astellas, Eyepoint, Genentech, Outlook, Regeneron, and Zeiss, and research fees from Regeneron and Zeiss.
